Omada Health (NASDAQ:OMDA - Get Free Report) had its price target boosted by research analysts at Evercore ISI from $21.00 to $23.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Evercore ISI's price target would suggest a potential upside of 30.16% from the stock's current price.
OMDA has been the subject of a number of other reports. Canaccord Genuity Group initiated coverage on shares of Omada Health in a research report on Tuesday, July 1st. They issued a "buy" rating and a $27.00 price target for the company. The Goldman Sachs Group initiated coverage on shares of Omada Health in a research report on Tuesday, July 1st. They set a "buy" rating and a $29.00 target price for the company. Barclays initiated coverage on shares of Omada Health in a research report on Tuesday, July 1st. They set an "overweight" rating and a $21.00 target price for the company. JPMorgan Chase & Co. initiated coverage on shares of Omada Health in a research report on Tuesday, July 1st. They set an "overweight" rating and a $19.00 target price for the company. Finally, Wall Street Zen upgraded shares of Omada Health to a "hold" rating in a research report on Monday, June 16th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $23.86.
View Our Latest Stock Analysis on Omada Health
Omada Health Trading Down 1.4%
Shares of OMDA traded down $0.25 during mid-day trading on Wednesday, reaching $17.67. The stock had a trading volume of 505,055 shares, compared to its average volume of 646,052. Omada Health has a 12 month low of $14.14 and a 12 month high of $28.40.
About Omada Health
(
Get Free Report)
Omada's mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.
Featured Articles

Before you consider Omada Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omada Health wasn't on the list.
While Omada Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.